Dexcom Stelo Glucose Biosensor System

Adopt with guardrails

Why

Real FDA clearance and real commercial scale (140K+ users / $22M FY24 revenue, plus a June 2026 pediatric clearance and 4-country international rollout) make this a legitimate, historically load-bearing ancestor of today's consumer metabolic-wearable category — but independent peer-reviewed evidence of degraded CGM accuracy in non-diabetic use, FDA's own no-alert/no-medical-decision caveat, and unresolved software-recall/reimbursement risk mean its maturity claims should not be taken at face value without guardrails.

Next

Log as the category-defining OTC-CGM ancestor of the Wearables & Human Augmentation discipline; before citing Stelo-derived consumer glucose/accuracy claims in downstream commerce or wisdom content, weight them against the 2025 AJCN independent-accuracy findings, and re-check FY2026 user/revenue and pediatric/international-rollout uptake once Dexcom reports it.